14 results about "Erysipelas" patented technology

The present application relates to a peptide-ionic liquid conjugate for the prevention and / or treatment of skin conditions. The peptide-ionic liquid conjugate comprises a pharmaceutical cosmetic peptide containing up to 10 amino acids and at least one ionic liquid containing a C1 to C18 saturated or unsaturated hydrocarbon chain substituent. The peptide-ionic liquid conjugates disclosed herein are useful for combating skin conditions, such as melanoma, non-melanoma skin cancer, diabetic foot ulcer, lower limb vein ulcer, stress ulcer, acne, candidiasis, cellulitis, dermatophytosis, erysipelas, folliculitis, impetigo, psoriasis, rosacea or eczema (atopic dermatitis), and the like. As they exhibit potent activity, bactericidal effect, anti-inflammatory and immunomodulatory effect and collagen production inducing effect on antibiotic sensitive strains or gram-positive and gram-negative multi-drug resistant clinical isolates. The present application further discloses topical compositions comprising the peptide-ionic liquid conjugates and uses thereof.

The present invention primarily relates to use of a compound of formula (I) as defined herein as an active ingredient. Moreover, it relates to methods for inhibiting or preventing the growth of one or more microorganisms and to a method for inhibiting or reducing the conversion of sweat components to odorous compounds. It also relates to a compound of formula (I) as defined herein for use in the treatment of inflammation, post-inflammatory hyperpigmentation, atopic dermatitis, bacterial vaginosis, tinea pedis, dermatitis exfoliativa neonatorum, impetigo contagiosa, furuncles and carbuncles, folliculitis, impetigo, and / or erysipelas, and for use as an antimicrobial agent, to a mixture comprising one or both compound(s) of formula (I) as defined herein, and to a mixture comprising one or both compound(s) of formula (I) as defined herein and one or more further antimicrobial agent(s). Finally, it relates to a deodorant, rinse-off product, and leave-on product as defined herein.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The preparation method comprises the following steps: selecting leaves and thin stems of any green-leaf herbal medicine with the effects of clearing heat, removing redness, relieving swelling and pain and activating blood circulation to dissipate stasis, drying and crushing the leaves and thin stems into fine powder, adding several times of water, a small amount of vaseline as a lubricant, sodium alginate as a water condensation thickener and a trace amount of potassium sorbate as a preservative, and uniformly mixing the materials. The green leaf hydrogel paste which is similar to the fresh herbal medicine paste in appearance, superior to the fresh herbal medicine paste in quality and same as the fresh herbal medicine paste in curative effect, is used for external treatment of acute joint sprain, traumatic injury, gout joint swelling and pain, skin furuncle and carbuncle sore, erysipelas, innominate pyogenic infections, poisonous insect stings and the like and can be produced in batches and stored for standby application can be obtained. And the medical plaster is an innovative medical plaster product on the market.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating erysipelas and a preparation method thereof. The traditional Chinese medicine composition comprises the following components: astragalus membranaceus, artemisia anomala, sappan wood, callicarpa macrophylla, winged euonymus twig, honeysuckle, purslane, lithospermum, sanguisorba officinalis, cacumen biotae and golden cypress. Pharmacodynamic experiments show that the traditional Chinese medicine composition obviously relieves lower limb swelling of erysipelas rats, reduces the content of NO in serum, increases the content of TNF-alpha in the serum, reduces the lesion score of lesion parts, and effectively improves related symptoms of erysipelas. The traditional Chinese medicine composition is wide in raw material source, easy to collect, simple in preparation process, high in safety, free of obvious adverse effects and free of adverse effects on the environment.

The present invention relates to the cosmetic use of phytosterols to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration. It further relates to a cosmetic treatment method comprising the topical application of phytosterols to at least one area of ​​skin, advantageously the scalp, to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration.Finally, it concerns phytosterols for their use in the treatment and / or prevention and / or reduction of the occurrence of a pathology associated with an alteration of the skin microbiota, in particular chosen from the group consisting of acne, psoriasis and bacterial and / or fungal infections, ulcers, herpes, boils, folliculitis, abscesses, sycosis, impetigo, ecthyma, erysipelas, mycoses such as candidiasis or dermatophytoses such as ringworm and / or scabies, pigmentary and / or acne scars as well as their combinations and / or in the treatment and / or prevention of superinfection of wounds and / or in the prevention of spots.

The application discloses an engineered bacillus subtilis strain for producing tagatose, a construction method and application thereof, and belongs to the technical field of bioengineering. The engineered strain takes bacillus subtilis as a host, co-expresses L-arabinose isomerase from Erysipelothrix larvae and beta-galactosidase from escherichia coli, and constructs the bacillus subtilis for co-expressing double enzymes through ribosome binding sites or promoters in series. The double-enzyme bacillus subtilis whole cell catalyzes lactose to produce D-tagatose, and the yield and conversion efficiency of D-tagatose are significantly improved after optimization of the enzymatic reaction. The application adopts single-strain double-enzyme co-expression and one-step whole-cell catalysis, uses low-cost lactose as a substrate, and has the advantages of mild reaction, less by-product, simplified process, no endotoxin safety hazard, and the like. The application solves the problems of low conversion rate, high substrate cost and complicated strain compounding in the prior art, and is suitable for industrialized production of food-grade D-tagatose.

The present invention relates generally to the use of a compound of formula (I) as defined herein as an active ingredient. Furthermore, the present invention relates to a method for inhibiting or preventing the growth of one or more microorganisms, and a method for inhibiting or reducing the conversion of sweat components to odorous compounds. The invention also relates to a compound of formula (I) as defined herein for use in the treatment of inflammation, post-inflammatory pigmentation, atopic dermatitis, bacterial vaginosis, tinea pedis, neonatal exfoliative dermatitis, contagious impetigo, furuncle and carbuncle, folliculitis, impetigo and / or erysipelas and for use as an antimicrobial agent, a mixture comprising one or two compounds of formula (I) as defined herein, and a mixture comprising one or two compounds of formula (I) as defined herein and one or more other antimicrobial agents. Finally, the present invention relates to a deodorant, a rinse-on product and a rinse-free product as defined herein.

The present invention relates to a vaccine comprising a non-replicating immunogen of swine erysipelothrix erysipelas and a non-replicating immunogen of porcine parvovirus, the use of a first vaccine in the prophylactic treatment of a pig against infection of erysipelothrix erysipelas and infection of porcine parvovirus by injecting the first vaccine into the corium layer of the pig.

A peptide-ionic liquid conjugate for the prevention and / or treatment of skin disorders. The peptide-ionic liquid conjugate comprises a cosmeceutical peptide comprising up to 10 amino acids and at least one ionic liquid comprising saturated or unsaturated hydrocarbon chain substituents from C1 to C18. The peptide-ionic liquid conjugates herein disclosed are suitable against skin disorders, such as, e.g., melanoma, non-melanoma skin cancers, diabetic foot ulcers, venous leg ulcers, pressure ulcers, acne, candidiasis, cellulitis, dermatophytoses, erysipelas, folliculitis, impetigo, psoriasis, rosacea, or eczema (atopic dermatitis), since they present potent activity against either antibiotic-susceptible strains or multidrug resistant clinical isolates of both Gram-positive and Gram-negative, a bactericidal type of action, anti-inflammatory and immunomodulatory effects, and collagenesis-inducing effects. Further disclosing a topical composition comprising the peptide-ionic liquid conjugates and uses thereof.

The present invention belongs to the field of biotechnology, and discloses a bivalent subunit vaccine of Streptococcus suis and swine erysipelas, and a preparation method and application thereof. The antigen components of the subunit vaccine are Streptococcus suis AbpB protein, Streptococcus suis AATS protein and swine erysipelas SpaA protein, the amino acid sequence of Streptococcus suis antigen protein AbpB is shown in SEQ ID NO.4, the amino acid sequence of Streptococcus suis antigen protein AATS is shown in SEQ ID NO.5, and the amino acid sequence of swine erysipelas antigen protein SpaA is shown in SEQ ID NO.6. The bivalent subunit vaccine of the present invention has good safety for target animal pigs, and has high immunogenicity, and "one shot for multiple protection" can effectively prevent and treat zoonotic diseases of Streptococcus suis and swine erysipelas.

The present invention belongs to the field of biomedicine technology, and specifically relates to the application of Atractylodes macrocephala polysaccharide in preventing and treating diarrhea caused by tyrosine kinase inhibitors. Specifically, the present invention has found through research that Atractylodes macrocephala polysaccharide inhibits CFTR-mediated chloride ion secretion in cells after treatment with the tyrosine kinase inhibitor pyrotinib. A certain dose of Atractylodes macrocephala polysaccharide can alleviate diarrhea in rats caused by pyrotinib and significantly restore intestinal barrier function. Atractylodes macrocephala polysaccharide treatment improves the distribution of intestinal microorganisms and restores the increased levels of Clostridium difficile and Erysipelothrix caused by pyrotinib. In short, the present invention provides ideas for the specific mechanism of Atractylodes macrocephala polysaccharide in alleviating diarrhea caused by pyrotinib, provides insights into the complex interactions between Atractylodes macrocephala polysaccharide and intestinal microbiota, and provides a possible strategy for using Atractylodes macrocephala polysaccharide to treat diarrhea caused by pyrotinib, and therefore has good practical application value.

The present invention primarily relates to use of a compound of formula (I) as defined herein as an active ingredient. Moreover, it relates to methods for inhibiting or preventing the growth of one or more microorganisms and to a method for inhibiting or reducing the conversion of sweat components to odorous compounds. It also relates to a compound of formula (I) as defined herein for use in the treatment of inflammation, post-inflammatory hyperpigmentation, atopic dermatitis, bacterial vaginosis, tinea pedis, dermatitis exfoliativa neonatorum, impetigo contagiosa, furuncles and carbuncles, folliculitis, impetigo, and / or erysipelas, to a mixture comprising one or both compound(s) of formula (I) as defined herein, and to a mixture comprising one or both compound(s) of formula (I) as defined herein and one or more further antimicrobial agent(s). Finally, it relates to a deodorant, rinse-off product, and leave-on product as defined herein.

The invention relates to a traditional Chinese medicine liniment for relieving swelling and pain and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine liniment is prepared from the following components in parts by weight: 40-60 parts of rheum officinale, 45-55 parts of radix angelicae, 50-55 parts of turmeric, 40-55 parts of golden cypress, 15-25 parts of rhizoma arisaematis, 15-20 parts of pericarpium citri reticulatae, 15-30 parts of rhizoma atractylodis, 20-25 parts of mangnolia officinalis, 15-25 parts of liquorice and 80-120 parts of radices trichosanthis. The traditional Chinese medicine liniment has the effects of clearing away heat and toxic materials, dispersing blood stasis, relieving swelling and pain and the like. The traditional Chinese medicine composition is widely used for eczema, acne, psoriasis, erysipelas, paronychia, soft tissue injury, acute cellulitis, acute suppurative lymphadenitis, perianal abscess, phlebitis, external humeral epicondylitis, gonarthromeningitis, swelling after fracture, burn and the like clinically.